We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.465 | 0.38% | 123.515 | 123.77 | 121.78 | 122.04 | 2,205,027 | 18:31:23 |
From May 2019 to May 2024
By Dominic Chopping
Danish pharmaceutical company Novo Nordisk A/S (NOV) said late Tuesday the U.S. Food and Drug Administration (FDA) has accepted a resubmitted application for insulin drugs Tresiba and Ryzodeg.
To preserve the integrity of the ongoing trial, only a small team within Novo Nordisk has access to the data, it said. This team has prepared the interim analysis for the resubmission and will interact with the FDA during the review.
It said Novo Nordisk management does not have access to the results of the interim analysis.
The trial is expected to be completed in the second half of 2016.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
